Hi friends,
I just posted on my blog the last of my ASH 2013 video interviews namely ASH 2013: Dr. Byrd on the New Data on Ibrutinib and Obinutuzumub in CLL.
We go into some detail, especially about obinutuzumab.
Brian
ASH 2013: Dr. Byrd on the New Data on Ibrutini... - CLL Support
ASH 2013: Dr. Byrd on the New Data on Ibrutinib and Obinutuzumub in CLL.
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
ASH 2013: Dr. John Pagel Discusses Radio-Immune Therapy (RIT) in Chronic Lymphocytic Leukemia (CLL)
Friends
In another interview from ASH 2013 that I just posted on my blog...
ASH 2013: INTERVIEW WITH DR. FURMAN RE: IDELALISIB
Hi friends
In my last blog post ( http://bkoffman.blogspot.com ), I have a short and interesting...
ASCO 2014: Dr. Susan O'Brien Reviews the 3 years follow-up Data on Ibrutinib in CLL
opportunity to post on my blog: http://bkoffman.blogspot.com some of the 3 year trial data on...
ASH 2017: Dr. Richard Furman on the importance of MCL-1 in CLL (chronic lymphocytic leukemia)
the deal in CLL. Only time and trials will tell.
Here is my interview with my friend and CLL...
Related Posts
- My 1 year CAR-T anniversary and from ASH 2018, Dr. Siddiqi on how CLL treatment has changed.
- ASH 2018: Dr. Kipps on antibodies and Venetoclax resistance
- ASH 2018: ECOG trial shows superiority of Ibrutinib and rituximab over FCR
- ASH 2018: Dr. Chadi Nabhan on the Cost of Ibrutinib vs. Chemo vs Chemoimmunotherapy in CLL and on way too much chemo being used.
- ASH 2018: Dr. Lindsey Roeker research from ASH 2018 on real world use of venetoclax for CLL
